

VU Research Portal

Translating the dynamics of genetics into health care practice

Rigter, T.

2014

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Rigter, T. (2014). *Translating the dynamics of genetics into health care practice*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

4

SEVERELY IMPAIRED HEALTH STATUS AT DIAGNOSIS OF POMPE DISEASE: A CROSS-SECTIONAL ANALYSIS TO EXPLORE THE POTENTIAL UTILITY OF NEONATAL SCREENING

Tessel Rigter
Stephanie S. Weinreich
Carla G. van El
Juna M. de Vries
Carin M. van Gelder
Deniz Güngör
Arnold J.J. Reuser
Marloes L.C. Hagemans
Martina C. Cornel
Ans T. van der Ploeg

Molecular Genetics and Metabolism 2012, 107(3): 448-455

ABSTRACT

Since the introduction of enzyme replacement therapy for Pompe disease, awareness and early diagnosis have gained importance. Because the therapy is most effective when started early and methods for dried bloodspot screening for Pompe disease are currently being explored, neonatal screening is getting increased attention. The objective of this study was to investigate the gains that might be achieved with earlier diagnosis by neonatal screening. For this purpose we analysed the health and functional status of non-screened patients with Pompe disease at the time of diagnosis.

Previously collected clinical data and results of an international patient reported questionnaire were used. Cross-sectional data of 53 patients with Pompe disease diagnosed between 1999 and 2009 (aged 0-64 years) were analysed. According to the World Health Organization's International Classification of Functioning, Disability and Health the following domains are described: body function, activity, participation and contextual factors.

In all patients with classic infantile Pompe disease cardiac function, hearing, muscle strength and motor development were considerably impaired at the time of clinical diagnosis. The use of oxygen and/or nasogastric tube-feeding was reported in more than 70% of these cases. Most children, adolescents and adults had advanced muscle weakness and impaired respiratory function at the time of their diagnosis, causing varying degrees of handicap. About 12% of them used a walking device and/or respiratory support at the time of diagnosis.

The severely impaired health status reported here provides a strong argument for earlier diagnosis and to further explore the potential of neonatal screening for Pompe disease.

INTRODUCTION

Pompe disease, or glycogen storage disease type II [OMIM ID: 232300], is an autosomal recessive lysosomal storage disorder. It is caused by a deficiency of acid alpha-glucosidase (GAA) [EC 3.2.1.20], which leads to glycogen accumulation in the lysosomes, predominantly resulting in progressive weakening of the muscles. The frequency of Pompe disease in the Netherlands is about 1/40,000¹. The genotype-phenotype correlation is largely understood in that the nature of the mutations in both GAA-alleles determines the degree of enzyme deficiency, but secondary genetic factors or non-genetic factors also contribute to the broad clinical spectrum of phenotypes seen within Pompe disease². Generalised hypotonia, respiratory difficulties and cardiomyopathy manifesting in the first months of life are characteristic features of the so-called classic infantile form of Pompe disease. Without treatment these patients die within the first year of life due to cardiorespiratory failure³. Other patients with Pompe disease have symptoms that can occur at any age, from early childhood until the sixth decade, and typically do not suffer from cardiomyopathy. In these patients the disease is characterized by a less progressive limb-girdle myopathy and decreased pulmonary function. When untreated these children, juveniles and adults with Pompe disease may become wheelchair-dependent or in need of respiratory support. Respiratory insufficiency is the major cause of death in these patients^{2,4}.

Enzyme replacement therapy (ERT) with recombinant human acid alpha-glucosidase (alglucosidase alfa), the first available treatment for Pompe disease, received market approval in Europe and the United States in 2006. Although not all patients respond equally well, the outcomes of treatment are promising. Previously published studies among patients with classic infantile Pompe disease (n=18, aged 1-6 months) showed a prominent effect of ERT on cardiac hypertrophy and function and a substantial effect on survival. However, 4 of the 18 studied patients died before the age of 36 months and half of the studied patients required invasive ventilation at age 36 months, at the time of death or by the end of the study⁵. In children and adults with Pompe disease (n=60, aged 15-70) treatment with ERT is associated with improved walking distance and stabilization of pulmonary function over an 18-month period^{6,7}. Clinical trials indicate a better clinical outcome if ERT is started early in the course of the disease^{5,8,9}. Due to rarity of the disease and the variation in disease presentation, the diagnosis of Pompe disease is often considerably delayed^{2,4}. In the Netherlands, the median age of symptom onset of classic infantile Pompe disease has been earlier described as 1.6 months, whereas the median age of diagnosis was around five months of age³. For the less progressive phenotypes a median doctors' delay of seven years has been described^{4,10}. Diagnosing patients in an earlier stage of the disease, or even before onset of symptoms, enables early intervention which could prevent or postpone further health damage.

The most promising option to enable earlier diagnosis is neonatal screening. It is conceivable to integrate the screening for Pompe disease into current neonatal screening programs. Recently it has been shown in Taiwan that nationwide testing of GAA-activity

in dried bloodspots substantially reduced the diagnostic delay for infants with classic infantile Pompe disease¹¹. This screening program confirms that early diagnosis and subsequent early treatment in babies with classic infantile Pompe disease could improve prognosis^{5,12,13}. An important disadvantage of the currently available blood-spot based tests is that at present they cannot distinguish between classic infantile Pompe disease and later onset phenotypes. This distinction can only be made by clinical follow-up and more extensive laboratory testing, which means that a positive bloodspot test could inform parents not only about the fact that their newborn child will develop classic infantile disease but also about the fact that their newborn child is likely to develop symptoms of Pompe disease at an unpredictable time-point later in life¹⁴. The early detection of adult-onset diseases is not a goal of current neonatal screening programs, although in the case of Pompe disease timely diagnosis could enable doctors to carefully follow their patients and install ERT promptly when indicated.

To explore the potential of a screening test, analytic validity, clinical validity, clinical utility and ethical, legal and social implications need to be reviewed¹⁵. It is already known that including Pompe disease in neonatal screening programs without being able to filter for classic infantile Pompe disease raises many social, ethical and legal issues^{16,17}. Analytic validity of various methods is being compared elsewhere^{18,19} and information on clinical utility will evolve from experiences with implemented programmes. An important step in investigating the clinical utility of neonatal screening for Pompe disease is to get better insight into the health damage which could potentially be averted or delayed by earlier diagnosis.

This report aims to quantify the health and functional status of both patients with classic infantile Pompe disease and patients with a less progressive phenotype at the time of diagnosis. It discusses to what extent patients with Pompe disease may be prone to health and functional damage for various domains (e.g. clinical parameters and limitations in activities) in order to explore the potential benefits of neonatal screening and subsequent early interventions for future patients with Pompe disease.

METHODS

In this study a retrospective inventory was made of the documented health and functional status of patients with Pompe disease within a year after diagnosis. Prospectively collected data from previously conducted studies on natural course and effectiveness of ERT (e.g.^{4,7,20,21}) were used to select relevant information. These data include clinical data from patient records and results from the IPA/Erasmus MC Pompe survey, an international patient reported questionnaire study. A confirmed diagnosis of Pompe disease by enzyme activity assay and/or DNA analysis was the main inclusion criteria. Patients with the classic infantile form characteristically had virtually no enzyme activity and completely deleterious mutations on both alleles, while children and adults with

late onset variants expressed at least one milder mutation. Further inclusion criteria for the present analysis were i) date of diagnosis between 1999 and 2009 and ii) less than one year between date of diagnosis and date of first visit at the Erasmus MC University Medical Center. These criteria were chosen to ensure adequate availability of patient records. Data were excluded when collected or referring to a moment more than a year after the year of diagnosis (for children and adults) or a moment more than 2 weeks after start of ERT (for classic infantile patients). Outcome measures of this study were chosen on the basis of the most apparent phenotypical characteristics of Pompe disease, which lie in the physical health domains of quality of life²². The selected data were used to describe patients' body function and structure (impairments), activity (limitations), participation (restrictions) and some contextual factors, following the International Classification of Functioning, Disability and Health²³.

Body function and structure impairments

The cardiac function and cardiac dimension of patients with classic infantile Pompe disease was examined by 2D M-mode echocardiography according to recommendations of the American Society of Echocardiography. The left ventricular mass index (LVMI) was used as a measure for hypertrophic cardiomyopathy and was expressed as the number of standard deviations from normal mean (z-scores)²⁴.

The hearing loss of patients with the classic infantile variant was evaluated by auditory brainstem evoked responses, oto-acoustic emissions, and impedance audiometry as previously described²¹.

To determine the degree of glycogen accumulation in the muscles and muscle damage of patients with classic infantile Pompe disease muscle biopsies from the M. quadriceps were used. Semi-quantitative data were obtained by histological examination with PAS-staining and evaluating the muscle fibres for their number of contractile elements. Muscle fibres were considered normal when surface area contained more than 75% contractile elements (see also²⁵).

Skeletal muscle strength of children and adults was measured by manual muscle testing using the Medical Research Council (MRC) grading scale (range 0-5, 20 muscle groups tested (see for details Figure 4.3))²⁶ and Hand-Held Dynamometry (HHD) (13 muscle groups tested (see for details Figure 4.2)) (Cytec dynamometer, CIT Technics, Haren, the Netherlands). The value measured by HHD (Newton) of each muscle group was expressed as percentage of the age- and sex-matched reference values (for children no reference value available for neck extensors)²⁷⁻²⁹.

The pulmonary function at the time of diagnosis was assessed by analysing data on forced vital capacity (FVC). FVC was measured in upright seated and supine position using a Lilly type pneumograph (Viasys Healthcare, Würzburg, Germany) or the KoKo spirometry system (Ferraris Respiratory, Louisville, USA). Measurements were performed according to ATS/ERS standards³⁰ and reference values were derived from published data³¹. Results were expressed as percentage of the predicted normal value.

Activity limitation

Activity limitation of classic infantile patients was assessed by the Alberta Infant Motor development Scale (AIMS)³². The AIMS score is a percentile score of the gross motor development, which depicts the child's development.

To assess the muscle function of older children and adults, the Quick Motor Function Test (QMFT) was used. This test describes to what extent patients experience difficulty with sixteen different actions (e.g. sit-ups, jumping etc.). Scores per action can range from 0 (not possible, or not executed for other reason) to 4 (completed action)³³.

Participation restriction

The Rotterdam Nine Items Handicap Scale (RHS) is used to assess the self-perceived ability to perform certain everyday tasks. Scores per task can range from 0 (not applicable) or 1 (not able to perform task) to 4 (perceiving no difficulty with task). When calculating the percentage of patients having problems with a certain task, scores of zero are excluded³⁴.

Contextual factors

Information on the use of walking devices, ventilators, or feeding support was collected from the patients' medical files and the IPA/Erasmus MC Pompe survey⁴.

Statistical analysis

Data were analysed using descriptive statistics in SPSS for Windows (version 15.0, SPSS inc., Chicago, IL, USA).

RESULTS

Data of 11 patients with classic infantile Pompe disease (median age at diagnosis: 1 month, range: 3-180 days), 13 affected children (median age at diagnosis: 10 years, range 0-16 years) and 29 adult patients (median age at diagnosis: 43 years, range: 24-68 years) met the inclusion criteria (see Table 4.1). There was an even gender distribution in this study population (not shown). Median time between diagnosis and date of collection of the data of patients with classic infantile Pompe disease was 12 days. Median time between first symptoms and diagnosis of the children in this study was 1 year (range 0-13) and in the adult patient group 8 years (range 0-43). Not all the selected parameters were available for all patients. Table 4.1 provides an overview of the age of the patients and number of patients included per test.

Classic infantile patients (n=11)

At the time of diagnosis the left ventricular mass index (LVMI) of the eleven patients with classic infantile Pompe disease ranged from 98g/m² to 599g/m² with a median of 231g/

Table 4.1 Available patient records: number and age of patients per test

Patient group n age: median (range) ^a	Classic infantile 11 1 (0.1-6.0) m	Affected children 13 10 (0-16) y	Affected adults 29 43 (24-68) y
Test			
Heart dimension (LVMI)	11 1 (0.1-6.0)		
Hearing loss (BERA)	11 1 (0.1-6.0)		
Muscle condition (biopsy)	9 1 (0.3-6.0)		
Motor development (AIMS)	11 1 (0.1-6.0)		
Muscle strength (HHD)		8 13 (8-16)	29 43 (24-68)
Muscle strength (MMT)		5 12 (4-14)	29 43 (24-68)
Pulmonary function (FVC)		8 ^b 14 (10-16)	29 43 (24-68)
Muscle function (QMFT)		8 13 (4-16)	29 43 (24-68)
Handicaps (RHS)			22 44 (34-64)

^a For classic infantile patients the median age and age range in the group is described in months (m), for children and adults in years (y).

^b FVC in sitting position. In supine position FVC was measured of 7 children (mean age: 13y, range: 7-16)

m², with reference values of 59.2 g/m² (normal mean), SD 7.9⁴. This shows that even the lowest LVMI found in the study population already deviates 4.9 times the standard deviation from normal mean. Systolic function was depressed in four patients.

Data on hearing from before or within a maximum of 10 days after start of ERT was available for all eleven patients with classic infantile Pompe disease. Nine out of the eleven patients described around diagnosis had sensorineural hearing loss, with estimated hearing thresholds ranging from 10-90dB. The nature of the hearing loss was mainly cochlear, although some patients also showed impaired middle-ear function, resulting in variable degrees of conductive hearing loss²¹.

Muscle biopsies of 9 infants with classic infantile Pompe disease were taken at the time of diagnosis. Analysis of the biopsies revealed that the samples contained 3-77% normal fibres when evaluated for the preservation of contractile elements, with a median of 49%. Figure 4.1A depicts the percentage-wise distribution of normal muscle fibres in the biopsies.

Motor development of all eleven infants was assessed at the time of diagnosis and all of them showed severe hypotonia and head lag. The percentile scores of the AIMS of the patients ranged from <1 to 50, with a median percentile score of 2. Five patients showed severe motor development delay (percentile score ≤ 5). The distribution of the percentile scores is depicted in Figure 4.1B.

At the time of diagnosis 4 of the 11 infants required supplemental oxygen and 7 required (partial) nasogastric tube-feeding.




Figure 4.1 Percentage normal muscle fibers in biopsies (A) (n=11)* and AIMS percentile scores (B) (n=11) of patients with classic infantile Pompe disease at the time of diagnosis. *Fibers with more than 75% surface area covered by contractile elements are considered normal.

Children (n=13) and adults (n=29)

The youngest child with Pompe disease without cardiac involvement was diagnosed directly after birth, due to an affected sibling. Of this patient only an AIMS-score (at the age of 3 months) was available from the tests selected for this research. The percentile score of this child was 5, which indicates a delay in motor development.

Data on hand-held dynamometry (HHD) around the time of diagnosis were available for 8 children (age 7-16) and all 29 adults (age 24-68). In 2 children the first HHD was performed more than one year after diagnosis and these data were therefore excluded. For 3 children (aged 0-2 years) no HHD data were available because they were too young to perform the test. The median HHD scores per muscle group were $\leq 80\%$ of the reference value for 4 muscle groups (hip abductor, knee flexor, hip flexor and shoulder abductor). The HHD scores for the individual muscle groups are depicted in Figure 4.2 as percentages of age- and sex-matched reference values (100%).

The manual muscle test (MMT) was performed in 29 adult patients and 5 affected children (age 4-14) at the time of diagnosis. Using the MRC scale, more than 50% of the patients had lost strength in the shoulder abductors, -adductors and -exorotators as well as the hip abductors, -adductors and -extensors (Figure 4.3). The lowest MRC score that was reported for a muscle group in our study population was 2 (only horizontal movement possible).

Data on the forced vital capacity (FVC) in both sitting and supine position at the time of diagnosis were available of 7 children and all 29 adults. FVC of one additional child was measured only in sitting position. Data of 2 children were excluded because pulmonary function was measured more than one year after diagnosis. No data were available on the pulmonary function of 5 children for various reasons, mainly




Figure 4.2 HHD scores per muscle group of 8 children and 29 adults with Pompe disease at the time of diagnosis. Percentage of normal value of age- and sex-matched normal population. (Dots depict minimum and maximum percentages). *For children no reference value for neck extensors was available.




Figure 4.3 Percentage of patients with loss of strength in different muscle groups at the time of diagnosis. MRC was measured in 20 muscle groups in adults and in 17 muscle groups in children. *Shoulder adductors and shoulder endo- and exorotators have not been evaluated in children.

because they were too young to perform the test. In sitting position the median FVC at diagnosis was 92% of normal (range 16%-140%), while the median FVC in supine position was 77% (range 20%-124%). In supine position the FVC was 80% or below (pathological threshold) for 18 adults and 3 children (58.3% of the tested patients).

Data from the Quick Motor Function Test (QMFT) performed at the time of diagnosis of 8 children and all 29 affected adults with Pompe disease was available. Not included were data of 3 children (aged, 2, 5 and 8) because the QMFT was only documented from measurements more than one year after diagnosis. Of 2 children with Pompe disease no data on the QMFT was available. The data show that at diagnosis more than 80% of them had difficulty with executing a sit-up from lying position or succeeded only partly. More than 50% of them had difficulties with or could only partly execute the following actions (scores under 4): getting up from a squat, or from one knee, squatting, jumping, stretching the legs in supine position, getting up from a chair, raising the torso from prone position, walking ten meters, picking up an object from the ground when standing or flexing the hip or knee in supine position. More than 40% of the patients described had difficulty with or could not stand on one leg and/or walk stairs. An overview of the results of the QMFT is depicted in Figure 4.4.

Data of twenty-two adults on the Rotterdam Handicap Scale were available and met the inclusion criteria (Figure 4.5). More than 70% of them at least sometimes needed




Figure 4.4 Percentage of affected children and adult patients with any difficulty executing different tasks at the time of diagnosis.




Figure 4.5 Rotterdam Handicap Scale results of adults at the time of diagnosis.

help with domestic tasks indoors and outdoors. More than 40% reported that they had difficulty with driving a car, travelling by bus and/or riding a bicycle and/or needed help with leisure activities outdoors. 15.8% of the patients (aged 34-64, median 44) reported that they were unable to fulfil their work or study at the time of diagnosis.

At time of diagnosis 2 adult patients (aged 43 and 64) were using a wheelchair and 4 adult patients (aged 36-64) were using non-invasive ventilation.

DISCUSSION

The delay in diagnosing Pompe disease was until now only described in terms of time i.e. number of years^{3,4,10}. Our study reporting on the condition of the patients at the time of diagnosis provides insight into the damage, which might be averted by early diagnosis and effective intervention. The data presented in this report reveal that patients with Pompe disease are significantly impaired in body function and structure, limited in activities, restricted in participation and in some cases dependent on respiratory-, walking- and/or feeding support already at the time of diagnosis.

The reported substantial loss of muscle fibres retaining normal contractile elements in classic infantile patients and low AIMS scores are particularly noteworthy, because the effect of ERT depends on preservation of intact muscle fibres and consequently residual muscle function at the start of treatment^{8,24,35}. Also the life-threatening cardiomyopathy found in these patients at diagnosis, which is known to normalize when treated promptly¹³ and the hearing loss which is irreversible²¹ emphasize the need for earlier diagnosis in patients with classic infantile Pompe disease. This study however also shows significant loss of muscle strength at the time of diagnosis of

children and adults with Pompe disease and consequently the loss of muscle function. Eighty percent of the patients had problems with executing a sit-up, 50% with getting up from a chair and 40% had difficulty with walking stairs at the time of diagnosis. The functional limitations had also significant consequences for daily functioning. At the time of diagnosis 80% experienced problems with domestic tasks outdoors, while almost 50% experienced limitations in performing their work or study. The fact that more than 20% of the adult patients were already either wheelchair bound and/or required respiratory support stresses the consequences of the delayed diagnosis. Part of these problems might have been prevented when patients were diagnosed and treated with ERT earlier^{7,20}. Given the progressive nature of Pompe disease, rapid in patients with classic infantile Pompe disease and slower in other patients, early diagnosis is in all cases expected to be associated with less tissue pathology, better preserved muscle function and fewer limitations in daily life at the start of treatment. Altogether the results of this study form a strong argument to advocate for earlier diagnosis for the whole spectrum of Pompe disease.

The patients described in this study include all patients seen in the Erasmus MC University Medical Center diagnosed between 1999 and 2009 who met the inclusion criteria. The median age at diagnosis of patients with classic infantile Pompe disease in this study was 30 days (range: 3-180 days). Since the literature³ describes a longer diagnostic delay than in our study-group this may mean that awareness has been raised during recent years resulting in earlier diagnosis or that our results may not be representative for all patients with classic infantile Pompe disease at diagnosis. However, because the reason for the earlier diagnosis in the current group is unknown, our results could be an under- or overestimate of the health and functional status of patients with classic infantile Pompe disease in general. Six children in our study group did not perceive any neuromuscular symptoms before being diagnosed. They were tested for Pompe disease following the diagnosis of a sibling or acting on findings from tests for other purposes indicating muscle or liver pathology. Therefore the time between first symptoms and diagnosis in this group (of 13 children) is rather broad and ranges between 0 and 13 years, with a median of 1 and a mean of 2.5 years. The diagnostic delay in our adult patient group (median delay 8 years, range 0-43 years) is similar to what has been described in the literature^{4,10}. Most missing data are assumed to be missing at random, so we presume they do not bias our conclusions. Unfortunately data on pulmonary and muscle function and muscle strength are missing for three of the five affected children under 5 years of age without cardiomyopathy, due to their inability to adequately perform the selected tests at a young age.

Neonatal screening seems an obvious choice to ensure the earliest diagnosis, mainly because of the bloodspot screening system that is already in place for other diseases in most developed countries. However, the currently available screening techniques for Pompe disease on blood spots do not discriminate between patients with classic infantile Pompe disease and less progressive variants of the disease^{14,36}.

Consequently, not only babies who need immediate treatment will be identified, but also seemingly healthy infants who will manifest symptoms at unpredictable age. For the latter patients and their parents this implies a constant awareness of a pre-symptomatic stage of the disease, while some cases may remain asymptomatic until the age of 70. Possible consequences for these so-called “patients in waiting”³⁷ have been discussed elsewhere^{16,17} as well as views of the public on this dilemma³⁸. Most of the current neonatal screening programs are aimed at detecting conditions that require immediate treatment. In this respect finding late-onset cases would be an unsought effect of the screening. This study, however, suggests that not only future patients with disease manifestations at very young age but also patients who would experience the first signs of disease much later in life might benefit from earlier diagnosis, as it allows for earlier intervention and presumably better treatment results. Consequences of early diagnosis for patients at the opposite ends of the clinical spectrum clearly need to be further explored.

CONCLUSION

This study quantifies the health and functional status of patients with Pompe disease and clearly shows that this is already severely impaired at the time of diagnosis. This is a strong argument to advocate for earlier diagnosis and to further explore the potential of neonatal screening.

REFERENCE LIST

- 1 Ausems MG, Verbiest J, Hermans MP, Kroos MA, Beemer FA, Wokke JH, Sandkuijl LA, Reuser AJ, van der Ploeg AT. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. *Eur. J. Hum. Genet.* 1999;7:713-716.
- 2 van der Ploeg AT, Reuser AJ. Pompe's disease. *Lancet.* 2008;372:1342-1353.
- 3 van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, Bakker HD, Loonen MC, de Klerk JB, Reuser AJ, van der Ploeg AT. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. *Pediatrics.* 2003;112:332-340.
- 4 Hagemans ML, Winkel LP, van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, van der Ploeg AT. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. *Brain.* 2005;128:671-677.
- 5 Kishnani PS, Corzo D, Leslie ND, Gruskin D, van der Ploeg AT, Clancy JP, Parini R, Morin G, Beck M, Bauer MS, Jokic M, Tsai CE, Tsai BW, Morgan C, O'Meara T, Richards S, Tsao EC, Mandel H. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. *Pediatr. Res.* 2009;66:329-335.
- 6 Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Li J, Dumontier J, Halberthal M, Chien YH, Hopkin R, Vijayaraghavan S, Gruskin D, Bartholomew D, van der Ploeg AT, Clancy JP, Parini R, Morin G, Beck M, de la Gastine GS, Jokic M, Thurberg B, Richards S, Bali D, Davison M, Worden MA, Chen YT, Wraith JE. Recombinant human acid [alpha]-glucosidase: major clinical benefits in

- infantile-onset Pompe disease. *Neurology*. 2007;68:99-109.
- 7 van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein MA, Zivkovic SA. A randomized study of alglucosidase alfa in late-onset Pompe's disease. *N. Engl. J. Med.* 2010;362:1396-1406.
 - 8 van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, de Klerk JB, Loonen MC, Vulto AG, Cromme-Dijkhuis A, Weisglas-Kuperus N, Hop W, van Hirtum H, van Diggelen OP, Boer M, Kroos MA, van Doorn PA et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. *Pediatrics*. 2004;113: e448-e457.
 - 9 Nicolino M, Byrne DR, Wraith JE, Leslie N, Mandel H, Freyer DR, Arnold GI, Pivnick EK, Ottinger CJ, Robinson PH, Loo JC, Smitka M, Jardine P, Tato L, Chabrol B, McCandless S, Kimura S et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. *Genet. Med.* 2009;11:210-219.
 - 10 Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, van der Ploeg AT. The natural course of non-classic Pompe's disease; a review of 225 published cases. *J. Neurol.* 2005;252:875-884.
 - 11 Chien YH, Chiang SC, Zhang XK, Keutzer J, Lee NC, Huang AC, Chen CA, Wu MH, Huang PH, Tsai FJ, Chen YT, Hwu WL. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. *Pediatrics* 2008;122:e39-e45.
 - 12 Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, Huang AC, Wu MH, Huang PH, Tsai FJ, Chen YT, Hwu JL. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. *Pediatrics* 2009;124:e1116-e1125.
 - 13 Chen LR, Chen CA, Chiu SN, Chien YH, Lee NC, Lin MT, Hwu WL, Wang JK, Wu MH. Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease. *J. Pediatr.* 2009;155:271-275.
 - 14 Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ, Hwu WL. Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. *J. Pediatr.* 2011;158:1023-1027
 - 15 Haddow JE, Palomaki GE. ACCE: A Model Process for Evaluating Data on Emerging Genetic Tests. in: Khoury M, Little J, Burke W (Eds.). *Human genome epidemiology: a scientific foundation for using genetic information to improve health and prevent disease.* Oxford University Press. 2003:217-233.
 - 16 Kwon JM, Steiner RD, "I'm fine; I'm just waiting for my disease": The new and growing class of presymptomatic patients, *Neurology* 77 (2011) 522-523.
 - 17 Laloui K, Wary C, Carlier RY, Hogrel JY, Caillaud C, Laforet P. Making diagnosis of Pompe disease at a presymptomatic stage: To treat or not to treat? *Neurology* 2011;77:594-595.
 - 18 Marsden D, Levy H. Newborn screening of lysosomal storage disorders. *Clin. Chem.* 2010;56:1071-1079.
 - 19 Mechtler TP, Sary S, Metz TF, de Jesus VR, Greber-Platzer S, Pollak A, Herkner KR, Streubel B, Kasper DC. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. *Lancet* 2012;379:335-341.
 - 20 Winkel LP, van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF, Loonen MC, Vulto AG, van Doorn PA et al. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. *Ann. Neurol.* 2004;55:495-502.
 - 21 van Capelle CI, Goedegebure A, Homans NC, Hoeve HL, Reuser AJ, van der Ploeg AT. Hearing loss in Pompe disease revisited: results from a study of 24 children. *J Inherit. Metab Dis.* 2010;33:597-602.
 - 22 Hagemans ML, Janssens AC, Winkel LP, Sieradzan KA, Reuser AJ, van Doorn PA, van der Ploeg AT. Late-onset Pompe disease primarily affects quality of life in physical health domains. *Neurology* 2004;63:1688-1692.
 - 23 World Health Organisation. *International classification of functioning, disability and health.* Geneva: WHO, 2001.
 - 24 Poutanen T, Jokinen E. Left ventricular mass in 169 healthy children and young adults assessed by three-dimensional echocardiography. *Pediatr. Cardiol.* 2007;8:201-207.
 - 25 van den Berg LEM, Drost MR, Schaart G, de Laat J, van Doorn PA, van der Ploeg AT, Reuser AJ. Muscle fiber-type distribution,

- fiber-type-specific damage, and the Pompe disease phenotype. *J Inherit. Metab Dis.* 2013;36:787-794.
- 26 Medical Research Council: Nerve Injuries Research Committee. His Majesty's Stationery Office. Aids to the investigation of peripheral nerve injuries. 1942.
 - 27 van der Ploeg RJ, Fidler V, Oosterhuis HJ. Hand-held myometry: reference values. *J Neurol. Neurosurg. Psychiatry* 1991;54:244-247.
 - 28 Andrews AW, Thomas MW, Bohannon RW. Normative values for isometric muscle force measurements obtained with hand-held dynamometers. *Phys. Ther.* 1996;76: 248-259.
 - 29 Beenakker EA, van der Hoeven JH, Fock JM, Maurits NM. Reference values of maximum isometric muscle force obtained in 270 children aged 4-16 years by hand-held dynamometry. *Neuromuscul. Disord.* 2001;11:441-446.
 - 30 Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, Macintyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. *Eur Respir. J* 2005;26:319-338.
 - 31 Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir. J* 1993;Suppl 16:5-40.
 - 32 Piper MC, Pinnell LE, Darrah J, Maguire T, Byrne PJ. Construction and validation of the Alberta Infant Motor Scale (AIMS). *Can. J Public Health* 1992;83(Suppl 2): S46-S50.
 - 33 van Capelle CI, van der Beek NA, de Vries JM, van Doorn PA, Duivenvoorden HJ, Leshner RT, Hagemans ML, van der Ploeg AT. The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients. *J Inherit. Metab Dis.* 2012;35:317-323.
 - 34 Hagemans ML, Laforet P, Hop WJ, Merckies IS, van Doorn PA, Reuser AJ, van der Ploeg AT. Impact of late-onset Pompe disease on participation in daily life activities: evaluation of the Rotterdam Handicap Scale. *Neuromuscul. Disord.* 2007;17: 537-543.
 - 35 Winkel LP, Kamphoven JH, van den Hout HJ, Severijnen LA, van Doorn PA, Reuser AJ, van der Ploeg AT. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy. *Muscle Nerve* 2003;27:743-751.
 - 36 Mechtler TP, Stary S, Metz TF, de Jesus V, Greber-Platzer S, Pollak A, Herkner KR, Streubel B, Kasper DC. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. *Lancet* 2012;379:335-341.
 - 37 Timmermans S, Buchbinder M. Patients-in-waiting: living between sickness and health in the genomics era. *J Health Soc. Behav.* 2010;51:408-423.
 - 38 Weinreich SS, Rigter T, van El CG, Dondorp WJ, Kostense PJ, van der Ploeg AT, Reuser AJ, Cornel MC, Hagemans ML. Public support for neonatal screening for Pompe disease, a broad-phenotype condition. *Orphanet. J Rare. Dis.* 2012;7:15.